# SPINRAZA Safety Profile and Clinical Study Overview

Keywords: SPINRAZA, SMA, 5q SMA, NURTURE study, safety profile, adverse events, lumbar puncture, clinical trials

> This page provides an overview of the safety profile of SPINRAZA based on the final 8-year analysis of the NURTURE study, along with details on its clinical trial design and key findings.

## Details
- [SPINRAZA Safety Profile](#): SPINRAZA demonstrated a favorable safety profile over 8 years, with no new safety concerns identified and no cases of meningitis, hydrocephalus, or organ failure reported.
- [Adverse Events](#): Adverse events were generally mild to moderate, with no serious events directly related to the study drug; lumbar punctures were well tolerated.
- [NURTURE Study Design](#): A Phase II open-label study evaluating SPINRAZA in pre-symptomatic infants genetically diagnosed with SMA, focusing on time to death or respiratory intervention.
- [Key Findings](#): The study showed long-term benefits, with the median time to respiratory intervention not estimable due to too few events.
- [References](#): Includes citations from published studies and conference presentations related to SPINRAZA and the NURTURE study.